About Me
Conditions and Treatments
colorectal cancer, mesothelioma, malignant mesothelioma, lymphoma, solitary fibrous tumor, thoracic cancer, small cell lung cancer, gastrointestinal cancer, mediastinal tumor, lung carcinoma, Kaposi sarcoma, anemia, platelet disorder, non-small cell lung cancer, AIDS-related malignancies, lung cancer, abdominal tumor, thymus cancer, breast cancer, AIDS-related lymphoma, blood cancer
Show More Conditions
Show More Conditions
Learn more about conditions we treat at NYU Langone:
Kaposi Sarcoma, Lung Cancer, Malignant Mesothelioma, AIDS-Related Lymphoma, Cutaneous T-Cell Lymphoma in Adults, Hodgkin Lymphoma in Adults, Non-Hodgkin Lymphoma in Adults, Primary Central Nervous System Lymphoma in Adults, Colorectal Cancer, Liver & Bile Duct Cancers, Small Intestine Cancer, Stomach Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Breast Cancer, Male Breast Cancer, Soft Tissue Sarcoma in Adults, Acute Lymphoblastic Leukemia in Adults, Acute Myeloid Leukemia in Adults, Chronic Lymphocytic Leukemia in Adults, Chronic Myelogenous Leukemia in Adults, Hairy Cell Leukemia in Adults, Myelodysplastic Syndromes, Myeloproliferative DisordersCredentials
Positions
- Clinical Associate Professor, Department of Medicine
Board Certifications
- American Board of Internal Medicine (Medical Oncology), 1987
- American Board of Internal Medicine - Internal Medicine, 1986
Education and Training
- Fellowship, Memorial Hospital for Cancer & Allied Diseases, Hematology/Oncology, 1988
- Residency, Bellevue Hospital Center, 1984
- MD from Johns Hopkins University, 1980
Departments
Is this your profile?
Edit profileIs this your profile?
Edit profileResearch My Research
Interests
hematologic abnormalities, liver disease, mycobacterial infections, hematologic growth factors
Research Interests Timeline
These focus areas and their associated publications are derived from PubMed and the MeSH term library.
represents one publication
Loading...
Publications
-
A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy [Meeting Abstract]
Cortes, J E; Altman, J; Ritchie, E K; Larson, R A; Claxton, D; Minden, M D; Goldenberg, A; Naoe, T; Yoon, S -S; Rousselot, P H; Mueller-Tidow, C; Del, Castillo T B; Havelange, V; Ciceri, F; Knopinska-Posluszny, W; Liu, S; Shrivastava, A; James, A J; Rich, E S; Bahceci, EJournal of clinical oncology. 2017 Jun 20; (2017):
-
Martin, Robert C G 2nd; Bruenderman, Elizabeth; Cohn, Allen; Piperdi, Bilal; Miksad, Rebecca; Geschwind, Jean-Francois; Goldenberg, Alec; Sanyal, Arun; Zigmont, Ellen; Babajanyan, Svetlana; Foreman, Pamela; Mantry, Parvez; McGuire, Brendan; Gholam, Pierre
American journal of surgery. 2017 Apr; 213(4):688-695
-
Wu, S E; Charles, H W; Park, J S; Goldenberg, A S; Deipolyi, A R
Diagnostic & interventional imaging. 2017 Jan; 98(1):37-42